The Synergistic Effects of Menopause and HIV on Cardiovascular Disease Risk in Women

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18+
SponsorUniversity of California, San Francisco

About this trial

Menopause is associated with the acceleration of many comorbidities, including cardiovascular disease. Whether HIV and menopause together increase cardiovascular disease risk is a key knowledge gap. The goal of this observational study is to address this knowledge gap by looking at the role of menopause on cardiovascular disease risk factors such as insulin resistance, hypertension, hyperlipidemia, and carotid atherosclerosis using previously collected data. The investigators will look at underlying causes for cardiovascular diseases worsening in menopausal women with HIV by looking at the role of increased inflammation in the body and whether this is altered by weight. The investigators achieve this by enrolling participants who are willing to undergo a whole body MRI.

Eligibility criteria

Qualifiers

90 non-pregnant women with HIV (approximately 30 in each menopausal phase) from the San Francisco MWCCS site.

Disqualifiers

Women who are not virally suppressed (HIV RNA >200 copies/mL)

Women who are not on antiretroviral therapy

Women who have a history of hysterectomy or oophorectomy

Women who are receiving treatment for active cancer or tuberculosis

Trial design

Treatments tested in this trial

  • Whole body MRI

Treatment groups

90 Participants
are divided into 1 treatment group

Sponsors and collaborators

University of California, San Francisco

Lead sponsor

National Heart, Lung, and Blood Institute (NHLBI)

Collaborator